The core is settled: neurotransmitters are real, essential to brain function, and the target of many effective medicines. What is genuinely mixed is how these chemicals produce complex states like mood, and how well we can measure them in a living brain. What is contested is the simple chemical-imbalance model of mental illness. As always, the question of cause stays separate from the question of whether treatments work.
One distinction to hold onto
Before grading anything, fix one habit in place. Two questions run through this whole field and must be kept apart. The first is about mechanism and cause: what a neurotransmitter does, and whether a shortfall of one causes a condition. The second is about effect: whether a treatment that acts on these chemicals helps people. A drug can help without our understanding why, and a mechanism can be real without any simple deficit story being true. Most of the heat in the popular argument comes from running these two together, so throughout the panels below, notice which question each claim is really answering.
The evidence, sorted three ways
The panels grade the main claims by how strong the evidence is. Green is settled, amber is mixed or evolving, red is genuinely contested. Contested does not mean unanswerable; it means reasonable researchers still disagree.
Neurotransmitters are real and essential. Neurons communicate chemically across synapses, and neurotransmitters carry those signals. This is backed by more than a century of work, from the discovery of chemical transmission to detailed maps of receptors and pathways, and it is not in serious scientific doubt.
Many effective drugs act on neurotransmitter systems, in well-understood ways. That an SSRI blocks serotonin reuptake, that caffeine blocks a drowsiness signal, that L-DOPA replenishes dopamine in Parkinson's disease, these mechanisms are clear. The precise molecular action of many medicines on this system is genuinely settled.
Broad roles for the main messengers are established. Glutamate as the chief excitatory signal, GABA as the chief inhibitory one, dopamine's central place in movement and reward learning: these broad-strokes functions are well supported, even though the fine detail in any given circuit is still being worked out.
How neurotransmitter systems produce complex states like mood is far from settled. We know these chemicals are involved in emotion, motivation, and stress, but the path from a molecule in a synapse to a felt experience runs through many circuits we have not fully mapped. Involvement is clear; a complete mechanistic account is not.
Measuring neurotransmitters in living human brains is hard. They act in tiny amounts, in tiny spaces, over fractions of a second, and cannot easily be sampled directly. Most precise data comes from animals or from indirect human methods, each with real limits. Claims about a person's real-time brain chemistry therefore deserve caution.
Why treatments that act on these systems help is still being worked out. Antidepressants that alter serotonin help many people on average, yet the reason the effect appears, whether through slow changes in neuroplasticity, emotional processing, or something else, remains an open question. Unknown mechanism is not the same as no effect.
The chemical-imbalance model of mental illness is contested, and in its most specific form not supported. The 2022 serotonin umbrella review found no consistent evidence that depression is caused by low serotonin. This is a claim about cause. It is separate from, and does not undercut, the evidence that antidepressants and therapy help many people.
Simplistic popular narratives about dopamine and serotonin are disputed. The dopamine detox, the serotonin dial, the idea that you can boost your feel-good chemicals to order: these run well ahead of the science. Each takes a real thread of what a messenger does and stretches it into a tidy story the evidence does not support.
How neurotransmitters are actually studied
Grading the evidence means knowing where it comes from. Different questions call for different methods, and each has characteristic strengths and blind spots. Matching a claim to the method that can support it is the whole craft of reading this literature well.
Animal and cellular studies
Much of what we know about the synaptic cycle comes from experiments on animals and isolated cells, where neurotransmitters can be measured and manipulated directly. These give precise mechanistic detail, but findings do not always transfer cleanly to the complexity of a human mind.
Randomised controlled trials
To ask whether a drug helps, people are randomly assigned to it or to a placebo, ideally blind to which. Pooling many such trials, as Cipriani and colleagues did for 21 antidepressants, gives the most reliable read on average effect, though it measures whether a drug works, not why.
Imaging and indirect measures
Techniques such as PET scanning can probe some neurotransmitter systems in living people, but indirectly and at coarse resolution. They have found real differences, yet no single reliable chemical marker that defines a mental condition, which is exactly why simple imbalance claims struggle.
The serotonin umbrella review
The 2022 review by Moncrieff and colleagues ran no new experiments; it pooled decades of studies to test one claim, that low serotonin causes depression, and found it unsupported. It is a model of isolating a single cause question from the separate matter of whether treatments help.
A few figures, in context
These come from large reviews and standard references. They are approximate, meant to give a sense of scale rather than false precision.
Reading the evidence honestly
The responsible summary is neither breathless nor dismissive. Neurotransmitters are real, essential, and the target of medicines that genuinely help many people. At the same time, the leap from a molecule in a synapse to a complex mental state is longer than confident slogans suggest, measuring these chemicals in living brains is hard, and the simple chemical-imbalance account of mental illness does not hold up. Holding all of that at once, a solid settled core, real open questions, and some popular stories that outrun the data, is what engaging with the science actually looks like.
It is worth naming why the topic runs hot. Brain chemistry sits where medicine, personal experience, and commerce meet, and each brings its own pull. Simple biological stories are easy to market and easy to remember; sceptical backlash can overshoot into denying that treatments work at all. Both flattenings are wrong. The evidence supports a more modest and more useful position: a genuinely important chemical layer of the mind, treatments that help many though not all, and real limits on how much any single molecule can explain. Be wary of anyone who tells you it is simpler than that in either direction.
A useful habit, when you meet a strong claim about neurotransmitters, is to ask which bucket it belongs in and which question it answers. Is it a settled point about mechanism, a mixed one about a complex state, or a contested one about the cause of an illness? And is it really telling you about cause or about effect? A remarkable amount of noise clears the moment those two checks are applied. The dopamine detox headline, the serotonin dial, the claim that a scan reveals your imbalance: each tends to collapse a mixed or contested question into a settled-sounding slogan, or to smuggle a claim about cause into what is really a claim about treatment. Sorting the claim honestly is not hard once you have the buckets in hand, and it is the most durable thing you can take from this page.
Where to go next
For the careful treatment of the imbalance question and how medication fits, read neurotransmitters and mental health. For the mechanics behind the drug claims, see how they work. And to revisit the messengers themselves, key neurotransmitters is the guide.
Sources
- Moncrieff J, Cooper RE, Stockmann T, Amendola S, Hengartner MP, Horowitz MA. The serotonin theory of depression: a systematic umbrella review of the evidence. Molecular Psychiatry. 2023;28:3243-3256.
- Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder. The Lancet. 2018;391(10128):1357-1366.
- Kandel ER, Schwartz JH, Jessell TM, et al. Principles of Neural Science. 6th ed. McGraw-Hill; 2021.
This page is educational and explains the state of neuroscience research. It is not medical advice and does not diagnose or treat any condition, and nothing here should be read as a reason to start or stop any medication.